Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Market Access Impact: Haemophilia A (US) 2018

Product Code:
596201118
Publication Date:
May 2018
Format:
PowerPoint
Price:
$5,345

Market barriers affect 14 percent of haemophilia A prescriptions in the US. Is your brand losing out?

Despite market barriers only affecting 14 percent of all haemophilia A prescriptions in the US, certain brands are losing on market share. Is it yours? Find out what’s driving share gains, and what your brand can do to level the playing field in Market Access Impact: Haemophilia A (US) [2018].

Based on a survey of 100 haematologists, the report covers 13 major therapies from Shire, Grifols, Bioverativ, CSL Behring, Bayer, Novo Nordisk, Octapharma and Pfizer. Handy graphs and charts reveal which  of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Interested in the European market? Click here to see the EU5 Edition.

Request sample pages

Top Takeaways

  • Barriers affect 14 percent of all prescriptions. Small, perhaps, but brands are still losing out on market share opportunities because of them. Is it cost, formulary issues or some other barrier combinations that cause the most amount of pain?
  • Two brands see the biggest share increases. But they’re not so far ahead that other brands can’t catch-up. Is your brand leading, or are you in the chasing pack?
  • One brand sees a significant loss. Despite being prescribed by over 50 percent of physicians, one brand loses nearly 1 percent of its market share because of barriers. Why? And can this be prevented?
  • Eliminating barriers would close the gap mid-table. Due to the overall barrier impact being 14 percent, changes at the top and bottom of the table won’t be seen if barriers are eliminated; not so mid-table, where changes would be seen.
  • Perception is not the problem. Across all 10 brands, awareness and a willingness to use is high. So what could be done to change market shares, and who could benefit the most?

Insight into 13 Major Haemophilia A Treatments

  • Advate (rurioctocog alfa; Shire)
  • Adynovate (rurioctocog alfa pegol; Shire)
  • Alphanate (factor VIII/von Willebrand factor concentrate; Grifols)
  • Eloctate (efmoroctocog alfa; Bioverativ/Sanofi)
  • Feiba (Anti-Inhibitor Coagulant Complex; Shire)
  • Hemlibra (emicizumab-kxwh; Roche)
  • Humate-P (Antihemophilic Factor/von Willebrand Factor Complex [Human]; CSL Behring)
  • Helixate FS (octocog alfa; CSL Behring)
  • Kovaltry (octocog alfa; Bayer)
  • Kogenate FS (octocog alfa; Bayer)
  • NovoEight (turoctocog alfa; Novo Nordisk)
  • Nuwiq (simoctocog alfa; Octapharma)
  • Xyntha (moroctocog alfa; Pfizer)

Exploring Market Access Barriers

Market Access Impact: Haemophilia A (US) [2018] explores key issues affecting haemophilia A drug manufacturers. You’ll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don’t, but would consider it?
  • Why don’t doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 100 US-based medical haematologists, chosen from the largest community of validated physicians in the world. All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with haemophilia A in total in the last month

We conducted the survey between May 3-15, 2018.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.

One brand sees a significant loss. Despite being prescribed by over 50 percent of physicians, one brand loses nearly 1 percent of its market share because of barriers. Why? And can this be prevented?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved